Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: a cross-sectional study
dc.authorid | Ayten Oğuz / 0000-0002-9518-8610 | en_US |
dc.authorid | Kamile Gül / 0000-0002-2145-770X | |
dc.authorscopusid | Ayten Oğuz / 35747046200 | |
dc.authorscopusid | Kamile Gül / 22834319800 | |
dc.authorwosid | Kamile Gül / CSZ-4495-2022 | |
dc.authorwosid | Ayten Oğuz / AAV-5193-2021 | |
dc.contributor.author | Oğuz, Ayten | |
dc.contributor.author | Şahin, Murat | |
dc.contributor.author | Tüzün, Dilek | |
dc.contributor.author | Kurutaş, Ergül B. | |
dc.contributor.author | Ülgen, Cansu | |
dc.contributor.author | Bozkuş, Özlem | |
dc.contributor.author | Gül, Kamile | |
dc.date.accessioned | 2021-07-14T12:25:57Z | |
dc.date.available | 2021-07-14T12:25:57Z | |
dc.date.issued | 2021 | en_US |
dc.department | İstinye Üniversitesi, Hastane | en_US |
dc.description.abstract | Abstract We aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO. Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ?95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients. The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (P<.05). From group 1 to group 3, BMI, FM, FM index, GS, myostatin, and A1c increased, and muscle mass percentage, HGS, and irisin decreased (P<.05). A positive correlation was found between FM/FFM and myostatin and a negative correlation between FM/FFM and irisin (r=0.303, P=.004 vs. r= 0.491, P<.001). Irisin remained an important predictor of SO, even after adjusting for confounding variables (OR:1.105; 95% CI:0.965–1.338, P=.002). The optimal cut-off value for irisin to predict SO was 9.49 ng/mL (specificity=78.1%, sensitivity=75.8%). In addition, A1c was an independent risk factor for SO development (OR:1.358, P=.055). This study showed that low irisin levels (<9.49ng/mL) and poor glycemic control in T2DM patients were an independent risk factor, especially for SO. Abbreviations: A1c = Glycosylated hemoglobin, ALT = Alanine aminotransferase, ASM = Appendicular skeletal muscle mass, BIA = Bioelectrical empedans analysis, BMI = Body mass index, CC = Calf circumference, CI = Confidence Interval, Cr = Creatinine, CV = Coefficients of variability, ELISA = Enzyme-linked immunosorbent assay, FFM = Fat-free mass, FFMI = Fat-free mass index, FM = Fat mass, FMI = Fat mass index, GS = Gait speed, HC = Hip circumference, HDL-C = High density lipoprotein, HGS = Hand-grip strength, HPLC = High-pressure liquid chromatography, IR = Insulin resistance, LDL-C = Low density lipoprotein, MAC = Mid-arm circumference, OR = Odds Ratio, ROC = Receiver operating characteristic, SD = Standard deviation, SMI = Skeletal muscle index, SO = Sarcopenic obesity, T2DM = Type 2 diabetes mellitus, TG = Triglyceride, Total-C = Total cholesterol, WC = Waist circumference, WHR = Waist-to-hip ratio | en_US |
dc.identifier.citation | Oguz, A., Sahin, M., Tuzun, D., Kurutas, E. B., Ulgen, C., Bozkus, O., & Gul, K. (2021). Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study. Medicine, 100(26), e26529. https://doi.org/10.1097/MD.0000000000026529 | en_US |
dc.identifier.doi | 10.1097/MD.0000000000026529 | en_US |
dc.identifier.endpage | 10 | en_US |
dc.identifier.issue | 26 | en_US |
dc.identifier.pmid | 34190188 | en_US |
dc.identifier.scopus | 2-s2.0-85110025066 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.startpage | 1 | en_US |
dc.identifier.uri | https://doi.org/10.1097/MD.0000000000026529 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12713/1923 | |
dc.identifier.volume | 100 | en_US |
dc.identifier.wos | WOS:000668300100047 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Oğuz, Ayten | |
dc.institutionauthor | Gül, Kamile | |
dc.language.iso | en | en_US |
dc.relation.ispartof | Medicine (Baltimore). | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Body Composition | en_US |
dc.subject | Myokine | en_US |
dc.subject | Obesity | en_US |
dc.subject | Type 2 Diabetes | en_US |
dc.title | Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: a cross-sectional study | en_US |
dc.type | Article | en_US |